Literature DB >> 19926546

Long-term results of the ABG-1 hydroxyapatite coated total hip arthroplasty: analysis of 111 cases with a minimum follow-up of 10 years.

R Bidar1, P Kouyoumdjian, E Munini, G Asencio.   

Abstract

INTRODUCTION: Medium-term studies of ABG-1 cementless total hip arthroplasty have shown favorable functional results with excellent femoral component fixation but an abnormally high rate of periacetabular component osteolysis, which may require early revision. HYPOTHESIS: The periacetabular osteolysis rate increases with time with the ABG-1 implant, leading to a high revision rate.
OBJECTIVE: The objective of this study was to test this hypothesis with a minimum follow-up of 10 years and evaluate the progression of periacetabular osteolysis and its consequences on implant fixation.
MATERIAL AND METHODS: A continuous series of 111 ABG-1 cementless prostheses implanted by a single operator with a theoretical minimum follow-up of 10 years. Seventy-five implants were analyzed with a mean follow-up of 13 years. All the prostheses had been implanted via a posterolateral approach and consisted of a 28 mm cup matching a head in zirconia and an antidislocation rim design high-density polyethylene insert.
RESULTS: Twelve cups were revised because of progressive retroacetabular osteolysis. The revisions were performed systematically although there was no pain or gross cup loosening. The revisions included resection of the granuloma, cavity filling with morselized bone grafts, and implantation of new uncemented ABG-2 cups in eight cases or cemented cups associated with a support ring in the four other cases. Thirty-two (48.5%) of the cups still in place at the end of the follow-up evaluation presented moderate and asymptomatic radiographic osteolysis, inciting close subsequent observation. No predictive factor of osteolysis onset was identified (age, body mass index, polyethylene wear, or cup orientation). None of the femoral stems was changed because of osteolysis: the only two femoral revisions resulted from periprosthetic fracture and one case of bipolar loosening. The femoral osteolysis images were small and all limited to zones 7a (18.8% of cases), 1a, and 1b (65.2% of cases). The overall survival rate of the series at 13 years of follow-up was 80.5%; the cup survival rate was 83.2%; the femoral implant, 94.3%; and failure of the femoral stem secondary to aseptic loosening was only 1.3%. DISCUSSION,
CONCLUSION: This long-term study confirms the high frequency of retroacetabular osteolysis of ABG-1 prostheses surpassing the osteolysis rate of other uncemented cups with a polyethylene insert. The absence of predictive criteria of osteolysis occurrence and the lack of symptoms warrants periodic follow-up of patients with ABG-1 cups and, if necessary, early repair of bone stock loss with grafts combined with acetabular cup revision. This procedure remains simple as long as performed before the onset of massive bone destruction, confirming the proposed revisions in this series were judicious. This study also confirms the excellent long-term fixation of the ABG-1 femoral stems derived from the osteointegration and proximal seal around the hydroxyapatite coating.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19926546     DOI: 10.1016/j.otsr.2009.10.001

Source DB:  PubMed          Journal:  Orthop Traumatol Surg Res        ISSN: 1877-0568            Impact factor:   2.256


  12 in total

1.  Enhanced osteoblast and osteoclast responses to a thin film sputtered hydroxyapatite coating.

Authors:  J Hao; S Kuroda; K Ohya; S Bartakova; H Aoki; S Kasugai
Journal:  J Mater Sci Mater Med       Date:  2011-05-13       Impact factor: 3.896

2.  The Results of Long-term Follow-up of Total Hip Arthroplasty Using Hydroxyapatite-coated Cups.

Authors:  Chang-Dong Han; Keun-Young Shin; Hyun-Hee Lee; Kwan-Kyu Park; Ick-Hwan Yang; Woo-Suk Lee
Journal:  Hip Pelvis       Date:  2015-12-30

3.  Bone Remodeling of Two Anatomic Stems: Densitometric Study of the Redesign of the ABG-II Stem.

Authors:  Juan J Panisello; Jorge Lopez; Marina Lillo; Jesus Mateo; Carlos Martin; Antonio Herrera
Journal:  Arthroplast Today       Date:  2020-07-03

4.  High 10-year survival rate with an anatomic cementless stem (SPS).

Authors:  Elhadi Sariali; Alexandre Mouttet; Philippe Mordasini; Yves Catonné
Journal:  Clin Orthop Relat Res       Date:  2012-03-09       Impact factor: 4.176

5.  Comparison of Physical-chemical and Mechanical Properties of Chlorapatite and Hydroxyapatite Plasma Sprayed Coatings.

Authors:  Imane Demnati; David Grossin; Olivier Marsan; Ghislaine Bertrand; Gérard Collonges; Christèle Combes; Maria Parco; Inigo Braceras; Joel Alexis; Yannick Balcaen; Christian Rey
Journal:  Open Biomed Eng J       Date:  2015-02-27

6.  Cementless hydroxyapatite coated hip prostheses.

Authors:  Antonio Herrera; Jesús Mateo; Jorge Gil-Albarova; Antonio Lobo-Escolar; Elena Ibarz; Sergio Gabarre; Yolanda Más; Luis Gracia
Journal:  Biomed Res Int       Date:  2015-02-23       Impact factor: 3.411

7.  The Effect of Hydroxyapatite Coating on Long-term Results of Total Hip Arthroplasty with Hydroxyapatite-coated Anatomic Femoral Stem.

Authors:  Young-Yool Chung; Chae-Hyun Im; Dae-Hee Kim; Ju-Yeong Heo; Young-Jae Jang
Journal:  Hip Pelvis       Date:  2014-09-29

8.  Survival of uncemented acetabular monoblock cups: evaluation of 210 hips in the Swedish Hip Arthroplasty Register.

Authors:  Rüdiger J Weiss; Nils P Hailer; André Stark; Johan Kärrholm
Journal:  Acta Orthop       Date:  2012-05-10       Impact factor: 3.717

Review 9.  Apatite formation: why it may not work as planned, and how to conclusively identify apatite compounds.

Authors:  Christophe Drouet
Journal:  Biomed Res Int       Date:  2013-07-29       Impact factor: 3.411

10.  Small and similar amounts of micromotion in an anatomical stem and a customized cementless femoral stem in regular-shaped femurs. A 5-year follow-up randomized RSA study.

Authors:  Mona Nysted; Olav A Foss; Jomar Klaksvik; Pål Benum; Kristin Haugan; Otto Schnell Husby; Arild Aamodt
Journal:  Acta Orthop       Date:  2014-04       Impact factor: 3.717

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.